Market Daily Brief: Gas giants merge, and a bid at a hefty price
Market Daily Brief
By Arthur Ledger: Sunday editorials and daily company notes
Monday brought deals: an all-stock merger of America's gas producers, a possible buyout of a surgery chain, and Europe's elevator makers still working through theirs. A deal tells you what someone else will pay. It does not tell you what a business is worth to a patient owner.
Oil, gilts and the Budget
Brent slipped 1.3% to $115.18 and US crude to $101.41, after a 6.2% rise last week to the highest weekly close in more than four years. Iranian strikes on tankers in the Strait of Hormuz keep the risk high; futures for April 2027 sit just under $100. The 10-year gilt yield touched 5.5% this month, the highest since 2007, and is now 5.37%. The FT puts the hole from higher borrowing costs and inflation near £12bn, and gilt investors want the fiscal rules kept with £15bn to £20bn of headroom when the Chancellor delivers the Budget on Wednesday.
Lloyds Banking Group: 11/20. It earns about 17% on tangible equity and trades at about 10.6 times earnings, but at 102p it costs about 1.8 times tangible book, and a higher bank surcharge may come on Wednesday. Even after a strong run, Lloyds is worth about a tenth of JPMorgan. A good franchise; the price already counts on a kind Budget.
The deals
EQT will buy Range Resources in an all-stock deal worth over $50bn including debt, creating America's largest gas producer. The filing sets 0.987 EQT shares per Range share, about $54.91, a 21% premium to Friday's close; closing is due in early 2027.
EQT: 11/20. Low-cost, debt cut from $9.3bn to about $5.5bn, about 13 times earnings and an 8% cash yield last year. But its share count has risen by issuing stock for deals, and gas prices set the result.
Range Resources: 12/20. Little debt, steady buybacks, and a fair premium for its owners. Its shares now move with EQT's.
Surgery Partners: 7/20, too hard. The FT says Bon Secours is close to a deal at about $20 a share against $15.75. No filing confirms it yet. After paying its doctor partners, the business made no owner cash in the first half, and debt is about six to seven times profit. A bid may help sellers. It does not make it a business we would own.
Kone: 13/20. Elevator servicing is a lovely business, earning about 35% on equity. But at about 30 times earnings, and with the €29bn TK Elevator deal adding about €14bn of debt and up to €5bn of forced European sales, we will wait. Results come on Wednesday.
Toyota: 9/20. It plans 400,000 humanoid robots and about $6.4bn a year of investment. At about 11.5 times guided earnings it looks cheap, but that guidance leans on investment gains, and margins are only about 6%.
Luxury and Tesla
Europe's six biggest luxury groups have lost €251bn of value this year. Third-quarter numbers from LVMH, Hermès and Kering all missed, though Hermès leather goods still grew 10.8%. Kering 8/20 (€179.90), Hermès 15/20 (€1,280) and LVMH 14/20 (€387.40) are all unchanged; prices are 3% to 5% below where we scored them.
Tesla 6/20, too hard, unchanged. Elon Musk cut his 2030 sales target from 20m vehicles to 5m while a Tesla-SpaceX merger is explored.
Mention only
- Camilla Cavendish warns that from Friday the Employment Rights Act gives unions access to UK firms with 21 or more staff.
- Deloitte and G-Research are private, Ming Yang is Chinese (excluded) and Bon Secours is a non-profit.
Also on our desk (since Saturday's article)
- Steele Bancorp 13/20 (Saturday X sweep): a small, profitable Pennsylvania bank at about 8 times earnings after one-offs and 1.45 times tangible book, but illiquid and nearly doubled in a year.
- Sunday's waiting list: American Express 15 (16 at about $265), MSCI 15 (clears around $450 to $480), GE Aerospace 15.
- Monday value brief: no new Berkshire letter or 13F; one small gift filing by Ajit Jain. Starboard is nominating directors at Knife River and Jana has a stake in Casella Waste (not scored).
- Copart stays 17/20; its next quarterly filing is not due yet.
Nothing new cleared 15 today. When deals and Budget nerves move prices, the patient investor's job is the same: know what a business earns, and wait for a price that leaves room for error.
Research only, not investment advice.
Chronicle
